A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer

Background: KRAS mutation, one of the most important biological processes in colorectal cancer, leads to poor prognosis in patients. Although studies on KRAS have concentrated for a long time, there are currently no ideal drugs against KRAS mutations. Methods: Different expression analysis and weigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Kangjia, Song, Yanni, Guan, Zilong, Ou, Suwen, Ye, Jinhua, Ran, Songlin, Wang, Hufei, Tao, Yangbao, Gong, Zijian, Ma, Tianyi, Jin, Yinghu, Huang, Rui, Gao, Feng, Yu, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237412/
https://www.ncbi.nlm.nih.gov/pubmed/35774610
http://dx.doi.org/10.3389/fphar.2022.899725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237412/
https://www.ncbi.nlm.nih.gov/pubmed/35774610
http://dx.doi.org/10.3389/fphar.2022.899725

Ejemplares similares